While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

For those preferring a drug-free approach to weight loss, research shows that certain nutrients and dietary strategies can naturally mimic the effects of semaglutides.

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Lars Rebien Sorensen becomes CEO after serving as the head of Novo's healthcare business. The company's enzymes business was ...

The common theme at the maker of Wegovy and at UnitedHealth may be investors' sudden awareness of cost-cutting pressure.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

People on GLP-1 medication seem to be adding more protein to their diets, further increasing demand for chicken and beef at a ...

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO ...